A Randomized Phase 3 Study of MRTX849 (Adagrasib) Versus Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation

UVA Tracking #
HSR210031
Principal Investigator
Ryan Gentzler
Contact
Maria Davenport
Contact Email
Contact Phone
434.297.4110
Official Trial Title
A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation
Study Description

The University of Virginia Cancer Center is conducting a clinical research study for patients who are adults ages 18 and over, and have non-small cell lung cancer with a KRAS G12C mutation. The purpose of this study to evaluate an investigational drug (MRTX849) versus chemotherapy (docetaxel) in patients with non-small cell lung cancer. The effects of the investigational drug alone will be evaluated for this study.

Participation includes 3 week cycles of treatment, with a longer term follow-up via a clinic visit or a phone call to keep track of how you’re doing. You may remain on the study as long as the treatment (investigational drug or chemotherapy) is still helping your disease. Study specific test will be provided at no cost to you.

Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT04685135

Compensation

Compensation: You will receive $50 per study visit. Reimbursement: You will receive up to $175 for hotel stays per night.